Cargando…

Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study

INTRODUCTION: This study aimed to assess treatment satisfaction and self-reported health status in insulin-naïve patients with type 2 diabetes mellitus (T2DM) who started insulin glargine basal-supported oral therapy (BOT) with glycated hemoglobin (HbA1c) value of ≥6.5%, using data from Add-on Lantu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukube, Shoko, Ikeda, Yukio, Kadowaki, Takashi, Odawara, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478177/
https://www.ncbi.nlm.nih.gov/pubmed/26040914
http://dx.doi.org/10.1007/s13300-015-0111-5
_version_ 1782377854024024064
author Tsukube, Shoko
Ikeda, Yukio
Kadowaki, Takashi
Odawara, Masato
author_facet Tsukube, Shoko
Ikeda, Yukio
Kadowaki, Takashi
Odawara, Masato
author_sort Tsukube, Shoko
collection PubMed
description INTRODUCTION: This study aimed to assess treatment satisfaction and self-reported health status in insulin-naïve patients with type 2 diabetes mellitus (T2DM) who started insulin glargine basal-supported oral therapy (BOT) with glycated hemoglobin (HbA1c) value of ≥6.5%, using data from Add-on Lantus(®) to Oral Hypoglycemic Agents 2 (ALOHA2) study, a 24-week single-arm, observational study of Japanese patients with T2DM, conducted as drug use surveillance in Japan. METHODS: Treatment satisfaction was measured using the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) and change version (DTSQc) and self-reported health status using EuroQol 5 Dimension (EQ-5D). The results were compared between the groups stratified by HbA1c level at the final evaluation point: target-achieved (<7.0%) and target-not-achieved groups (≥7.0%). RESULTS: In 1251 patients (336 in the target-achieved group), scores of DTSQs, DTSQc, and EQ-5D indicated significant improvement from baseline to the final evaluation point (both P < 0.01). The mean change in DTSQs scale score, DTSQs item score, and EQ-5D index score, and mean DTSQc scale score were significantly improved in the target-achieved group compared with the target-not-achieved group (P < 0.05 for all). DTSQs scale score and HbA1c level showed the same pattern of chronological change. Data analysis in patients stratified by DTSQs score showed better glycemic control in the high satisfaction group. CONCLUSION: Following insulin glargine BOT introduction, treatment satisfaction and health status were improved from patients’ perspectives despite the need for daily injections. Based on the possible association between HbA1c 7.0% level achievement, treatment satisfaction, and health status, better glycemic control may be a key to successful treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-015-0111-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4478177
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-44781772015-06-30 Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study Tsukube, Shoko Ikeda, Yukio Kadowaki, Takashi Odawara, Masato Diabetes Ther Original Research INTRODUCTION: This study aimed to assess treatment satisfaction and self-reported health status in insulin-naïve patients with type 2 diabetes mellitus (T2DM) who started insulin glargine basal-supported oral therapy (BOT) with glycated hemoglobin (HbA1c) value of ≥6.5%, using data from Add-on Lantus(®) to Oral Hypoglycemic Agents 2 (ALOHA2) study, a 24-week single-arm, observational study of Japanese patients with T2DM, conducted as drug use surveillance in Japan. METHODS: Treatment satisfaction was measured using the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) and change version (DTSQc) and self-reported health status using EuroQol 5 Dimension (EQ-5D). The results were compared between the groups stratified by HbA1c level at the final evaluation point: target-achieved (<7.0%) and target-not-achieved groups (≥7.0%). RESULTS: In 1251 patients (336 in the target-achieved group), scores of DTSQs, DTSQc, and EQ-5D indicated significant improvement from baseline to the final evaluation point (both P < 0.01). The mean change in DTSQs scale score, DTSQs item score, and EQ-5D index score, and mean DTSQc scale score were significantly improved in the target-achieved group compared with the target-not-achieved group (P < 0.05 for all). DTSQs scale score and HbA1c level showed the same pattern of chronological change. Data analysis in patients stratified by DTSQs score showed better glycemic control in the high satisfaction group. CONCLUSION: Following insulin glargine BOT introduction, treatment satisfaction and health status were improved from patients’ perspectives despite the need for daily injections. Based on the possible association between HbA1c 7.0% level achievement, treatment satisfaction, and health status, better glycemic control may be a key to successful treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-015-0111-5) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-06-04 2015-06 /pmc/articles/PMC4478177/ /pubmed/26040914 http://dx.doi.org/10.1007/s13300-015-0111-5 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Tsukube, Shoko
Ikeda, Yukio
Kadowaki, Takashi
Odawara, Masato
Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
title Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
title_full Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
title_fullStr Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
title_full_unstemmed Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
title_short Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
title_sort improved treatment satisfaction and self-reported health status after introduction of basal-supported oral therapy using insulin glargine in patients with type 2 diabetes: sub-analysis of aloha2 study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478177/
https://www.ncbi.nlm.nih.gov/pubmed/26040914
http://dx.doi.org/10.1007/s13300-015-0111-5
work_keys_str_mv AT tsukubeshoko improvedtreatmentsatisfactionandselfreportedhealthstatusafterintroductionofbasalsupportedoraltherapyusinginsulinglargineinpatientswithtype2diabetessubanalysisofaloha2study
AT ikedayukio improvedtreatmentsatisfactionandselfreportedhealthstatusafterintroductionofbasalsupportedoraltherapyusinginsulinglargineinpatientswithtype2diabetessubanalysisofaloha2study
AT kadowakitakashi improvedtreatmentsatisfactionandselfreportedhealthstatusafterintroductionofbasalsupportedoraltherapyusinginsulinglargineinpatientswithtype2diabetessubanalysisofaloha2study
AT odawaramasato improvedtreatmentsatisfactionandselfreportedhealthstatusafterintroductionofbasalsupportedoraltherapyusinginsulinglargineinpatientswithtype2diabetessubanalysisofaloha2study